Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.82Last Year’s EPS
-0.91Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: -59.63%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in UGN-102's FDA review process, strong clinical trial results, and a substantial market opportunity. JELMYTO's revenue growth and a strong financial position also contribute positively. However, there are concerns about the single-arm nature of the ENVISION trial, increased expenses, and net loss. The highlights and lowlights are relatively balanced.Company Guidance
During UroGen Pharma's first-quarter 2025 earnings call, the company provided detailed guidance on several key metrics and strategic initiatives. They highlighted the potential impact of their lead candidate, UGN-102, which is under FDA review with a PDUFA target date of June 13th, 2025. UGN-102 is expected to be UroGen's primary growth driver, with an estimated market opportunity exceeding $5 billion, targeting approximately 60,000 patients annually. The company reported first-quarter JELMYTO sales of $20.3 million, reflecting an 8% year-over-year increase. As part of their commercialization strategy, UroGen plans to expand their sales force from 50 to over 80 representatives by launch. The company also reported having $200.4 million in cash, cash equivalents, and marketable securities as of March 31st, 2025, ensuring a strong financial footing to support their growth and commercialization efforts.UGN-102 FDA Review Progress
UGN-102 is in the final stages of FDA review with a PDUFA target date of June 13th. An ODAC meeting is scheduled for May 21st, and the company is well-prepared to present a strong case for approval.
Strong Clinical Trial Results
Updated data from the pivotal ENVISION trial showed that 80.6% of patients who achieved a complete response at three months remained in response at 18 months.
Commercial Readiness and Market Opportunity
UGN-102 represents a transformative growth opportunity, targeting an addressable population of approximately 60,000 patients annually and a market opportunity of over $5 billion.
JELMYTO Revenue Growth
Reported $20.3 million in first-quarter sales, an 8% year-over-year growth compared to the first quarter of 2024, driven by underlying demand growth of 12%.
Strong Financial Position
Supported by a strong balance sheet with over $200 million in cash, cash equivalents, and marketable securities as of March 31st, 2025.
URGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
URGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $10.38 | $11.14 | +7.32% |
Mar 10, 2025 | $9.82 | $9.92 | +1.02% |
Nov 06, 2024 | $12.21 | $12.24 | +0.25% |
Aug 13, 2024 | $14.51 | $14.96 | +3.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Urogen Pharma (URGN) report earnings?
Urogen Pharma (URGN) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Urogen Pharma (URGN) earnings time?
Urogen Pharma (URGN) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is URGN EPS forecast?
URGN EPS forecast for the fiscal quarter 2025 (Q2) is -0.82.